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ABSTRACT  
 
Background: Enteric hyperoxaluria (EH) occurs with a rate of 5-24% in patients with 
inflammatory bowel disease, ileal resection, and modern bariatric surgery. The 
excessive absorption of calcium oxalate causes chronic kidney disease (CKD) in 
patients with EH. In the literature, a single experience was reported in combined 
intestine-kidney transplantation (CIKTx) in patients with CKD due to EH. 
Methods: After a report of two successful cases of CIKTx in patients with EH and CKD, 
one was performed at our center in a 59-year-old Caucasian female who developed 
intestinal failure with total parenteral nutrition (TPN)-dependence after a complication 
post-bariatric surgery. Before CIKTx, she underwent kidney transplantation alone (KTA) 
twice which failed due to oxalate nephropathy.  
Results: In July 2014, the patient underwent CIKTx and bilateral allograft nephrectomy 
to avoid EH and oxalate stone burden. The post-operative course was complicated with 
acute tubular necrosis due to the use of high pressors related to perioperative bleeding. 
The patient was discharged 79 days after CIKTx with a serum creatinine (s-Cr) of 1.2 
mg/dL and TPN-free. Her s-Cr increased at 7 months and a renal biopsy showed 
oxalate nephropathy. SLC26A6 (oxalate transporter) staining was significantly 
diminished in native duodenum/rectum as well as in intestinal allograft compared to 
control. 
Conclusions: KTA in patients with CKD secondary to EH should not be recommended 
due to high risk of recurrence. Although other centers showed good long-term outcomes 
in CIKTx, our patient experienced recurrence of EH due to oxalate transporter defect, 
early kidney allograft dysfunction, and prolonged antibiotic use.   
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ABBREVIATIONS 
 
CIKTx = combined intestine-kidney transplantation 
CKD = chronic kidney disease 
eGFR = estimated glomerular filtration rate 
ITx = intestinal transplantation 
SMA = superior mesenteric artery 
SMV = superior mesenteric vein 
TPN = total parenteral nutrition 
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INTRODUCTION 
A treatment option for intestinal failure in patients with severe complications of total 
parenteral nutrition (TPN) is intestinal transplantation (ITx) (1). A recent report from the 
Intestinal Transplant Registry (2,887 various types of ITx from 82 international programs 
between 1985-2012) showed current actuarial patient survival rates of 76%, 56%, and 
43% at 1, 5, and 10 years, respectively (2). In contrast, patients requiring combined 
intestine/multivisceral and kidney transplantation showed lower patient survival rates 
than intestine/multivisceral transplants alone (3,4).  
 
Enteric hyperoxaluria (i.e., secondary hyperoxaluria) is a frequent complication of 
inflammatory bowel diseases, ileal resection, and modern bariatric surgery (5-8). The 
prevalence of enteric hyperoxaluria has been estimated at 5-24% of all patients with 
gastrointestinal diseases associated with malabsorption (8,9). It does not have a genetic 
predisposition like primary hyperoxaluria, except genetic variations of intestinal oxalate 
transporters, such as SLC26A6 (9-10). It is primarily due to the excessive absorption of 
calcium oxalate (9), which causes chronic kidney disease (CKD) requiring renal 
replacement therapy (8).  
 
Patients with enteric hyperoxaluria requiring kidney transplantation are at risk of the 
recurrence of disease and calcium oxalate deposition in the renal allograft, which will 
cause CKD and eventually the loss of the renal allograft. Ceulemans and colleagues 
(11) reported 2 cases of combined intestine-kidney transplantation (CIKTx) in patients 
with enteric hyperoxaluria secondary to intestinal failure. In both cases, patients were in 
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hemodialysis and TPN-dependent at the time of transplantation and became dialysis 
and TPN-free after CIKTx at 11 months of follow-up in one case, and at almost 6 years 
of follow up in another case.  
 
We here report our experience in a patient with enteric hyperoxaluria and CKD who 
underwent CIKTx.  
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METHODS AND RESULTS 
 
A 59-year-old Caucasian female (KD, weight: 82 kg, length: 167 cm, BMI: 29.4, blood 
group A+) had a bariatric gastric bypass surgery in 2002 when she was 43 years old. 
Two years after her bariatric surgery, she underwent a bowel resection due to cecal 
volvulus and developed intestinal failure and TPN-dependence. At that time, her serum 
creatinine was 1.2 mg/dL and estimated glomerular filtration rate (eGFR) was >60 
mL/min/1.73m2. She then gradually developed CKD (5 years after she was diagnosed 
with intestinal failure). Despite administration of calcium carbonate and restricted 
oxalate diet, she was diagnosed with CKD stage 5, and started intermittent 
hemodialysis in March 2009 (Figure 1). A biopsy of the native kidney showed severe 
oxalate nephropathy and 24h urine oxalate measured by Litholink (Chicago, IL) resulted 
60 mg/day.  
 
At this point, the diagnosis of enteric hyperoxaluria was made. She received her first 
kidney transplantation in July 2009 from a living donor. She underwent bilateral native 
nephrectomy due to oxalate stone burden 15-months after her kidney transplantation. 
Unfortunately, hyperoxaluria recurred and she developed CKD again, 15-months after 
the kidney transplantation. A biopsy of the renal allograft showed severe oxalate 
nephropathy and 24h urine oxalate was 60 mg/day. She went back on hemodialysis in 
May 2011. Five months after being on hemodialysis, another living donor became 
available to her and she underwent her 2nd kidney transplantation in October 2011 when 
she was 52 years old (Figure 1). Less than a year after her 2nd kidney transplantation, 
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she developed CKD and the allograft biopsy showed severe oxalate nephropathy in 
September 2012 (Figure 2A). About 2 years after her 2nd kidney transplantation, she 
was diagnosed with CKD stage 5 and she restarted on hemodialysis.  
 
In July 2014, when she was 59 years old, a 9-year-old female deceased donor became 
available. Both T and B cell cross-matches were negative and both class I and II panel 
reactive antibodies were 0. She underwent combined intestine-kidney (3rd) 
transplantation to avoid enteric hyperoxaluria related to her intestinal failure. At the 
same time, she also underwent bilateral allograft nephrectomy (2 previous kidney 
transplants) to avoid oxalate stone burden. The intestine (which included the entire 
jejunum, entire ileum, ileocecal valve, cecum, ascending colon, and transverse colon) 
was transplanted by anastomosing the donor superior mesenteric artery (SMA) to the 
recipient SMA and the donor superior mesenteric vein (SMV) to the recipient SMV. 
Proximally, the bowel anastomosis was performed in side-to-side fashion between 
donor and recipient jejunum. Distally, the donor transverse colon was anastomosed to 
the recipient sigmoid colon in end-to-side fashion without creating any stoma. After the 
transplantation of the intestine, the kidney was transplanted in the left iliac fossa 
intraperitoneally anastomosing renal artery to the external iliac artery and renal vein to 
the external iliac vein in end-to-side fashion. The ureter was anastomosed using Lich-
Gregoir technique with double J stent. The immunosuppressive regimen was consisted 
of induction of antithymocyte globulin (2 mg/kg x 3 doses), rituximab (150 mg/m2 x 1 
dose), and methylprednisolone (3 boluses only with antithymocyte globulin induction). 
The maintenance immunosuppression included tacrolimus (12h trough levels of 10 
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ng/mL in the first 3 months and 8 ng/mL thereafter) and mycophenolate mofetil (1000 
mg x2/ daily). Due to the development of leukopenia and persistent diarrhea 
mycophenolate mofetil was discontinued at 2 months and azathioprine (100 mg/daily) 
was added once leukopenia resolved. 
 
The post-operative course was complicated with acute tubular necrosis and delayed 
graft function of the kidney allograft due to (i) the use of high pressors related to 
intraoperative bleeding and (ii) hemorrhage due to the accidental removal of a femoral 
arterial line on post-operative day 1. The patient had a significant left groin hematoma 
requiring several units of blood and blood products transfusion. She was placed on a 
continuous veno-venous hemodialysis for 7 days. On post-operative day 15, she 
developed a urinary tract infection for which she was treated with cefepime for 10 days. 
She was also treated for several blood stream and urinary tract infection episodes with 
daptomycin, linezolid, meropenem, and micafungin, and their combinations until 
discharge. On post-operative day 25, she developed an acute kidney injury and renal 
dysfunction due to high levels of tacrolimus for which she was supported with a 
continuous veno-venous hemodialysis for another 12 days.  
 
The patient experienced prolonged diarrhea despite the use of anti-motility agents and 
couldn’t gain weight. Stool fat and stool pancreas elastase were measured. Although 
stool fat was normal, pancreas elastase was low in the stool (<50microElastase/gm 
stool), indicating exocrine pancreas insufficiency. The patient started pancrealipase 
orally and she experienced more formed stools, gained weight with improved 
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prealbumin levels. Despite exocrine pancreas insufficiency, her endocrine pancreas 
function was normalized 15 days after the transplant (high blood glucose in the first 15 
days probably due to steroid induction). The patient was discharged on post-operative 
day 79 dialysis-free with a serum creatinine of 1.2 mg/dL and TPN-free.  
 
She developed a slow deterioration of her renal function over the next 3 months (6 
months post-transplant). At 7 months after the 3rd kidney transplantation (March 2015), 
her serum creatinine was 3.3 mg/dL (Figure 3). A biopsy of the renal allograft showed 
intraluminal oxalate crystals, oxalate nephropathy, and Banff Ia acute cellular rejection 
(Figure 2B), which was treated with steroid boluses and IV fluids. Her 24h urine oxalate 
level was 38 mg/day (Figure 1). Although she is currently TPN-free, she has started on 
hemodialysis on March 2016 (20 months after CIKTx). 
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DISCUSSION 
 
 
Enteric hyperoxaluria and related renal dysfunction was first described in early 70ies as 
acquired hyperoxaluria in patients (both adults and children) with resection of the distal 
ileum (5,6). Several medical strategies have been applied to reduce oxalate absorption, 
such as reduced oxalate or oxalate-free diets, administration of oral calcium and 
magnesium salts, and more recently the use of oxalate degrading bacteria (Oxalobacter 
formigens) containing probiotics (9).  
 
The problem of enteric hyperoxaluria progressing to CKD became more evident despite 
abovementioned medical therapies since early 2000 with an increase in modern 
bariatric surgeries (12). Kidney transplantation alone was reported in patients with CKD 
secondary to enteric hyperoxaluria with (13,14) or without (15,16) success.    
 
Despite several CIKTxs were reported by the Intestinal Transplant Registry, the first and 
only report on CIKTx in patients with enteric hyperoxaluria and CKD was published in 
2013 by Ceulemans and colleagues (11). They reported 2 successful cases of the 
resolution of intestinal failure and CKD secondary to enteric hyperoxaluria following 
CIKTx. After Ceulemans et al.’s success, we reevaluated our patient after 2 failed 
kidney transplantations due to the recurrence of enteric hyperoxaluria.  
 
In our case, the genetic testing was performed to exclude primary hyperoxaluria 
between the first and second kidney transplantation. All 3 subtypes of primary 
hyperoxaluria were tested for AGXT, GRHPR, and DHDPSL gene mutations, which 
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resulted negative. Negative results were interpreted as the patient having <0.5% of 
chances of genetic defect in her oxalate metabolism. There was no bone or heart 
involvement due to hyperoxaluria. Her liver enzymes were also completely normal. It 
was then decided to proceed with her second kidney transplantation. After the failure of 
2nd kidney transplantation, we repeated all genetic testing for primary hyperoxaluria and 
performed a liver biopsy to decide whether we should have proceeded with combined 
multivisceral (which includes the liver) and kidney transplantation or isolated intestine 
and kidney (3rd) transplantation. Genetic testing for all subtypes of primary 
hyperoxaluria resulted negative again. The liver biopsy showed normal liver architecture 
and hepatocytes with no fibrosis (not shown). Clinically, all liver function tests were 
normal. It was then decided to proceed with CIKTx instead of multivisceral transplant 
and kidney transplantation. 
 
Post-operatively, our patient experienced the delayed graft function of the renal allograft 
due to perioperative complications. She was on warfarin therapy before transplant due 
to deep venous thrombus in her right leg. Despite careful hemodynamics and correction 
of her high INR, she required increased volume of blood and blood product transfusions 
during the transplant surgery, which also included two allograft nephrectomies. The 
hemorrhage after an accidental removal of a femoral arterial line was difficult to control. 
She developed a big hematoma in her leg and thigh and required several units of blood 
transfusion, which added another burden on the function of the renal allograft.  
 
In order to exclude another genetic defect in oxalate transporter (SLC26A6) as shown 
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by Capolongo et al (10), biopsies from patient’s native duodenum, native rectum, and 
intestine allograft (x2 – 4 and 10 months after CIKTx) were stained (Figure 4). Although 
the normal intestinal mucosa (from the 3rd party, served as control) showed intense 
staining of the subnuclear as well as supraneuclear cytoplasm of the epithelial cells, 
biopsies of native duodenum and rectum from our patient, and the small intestinal 
allograft showed a significant less intensity of staining. Furthermore, staining was 
restricted to the subnuclear portion of the cytoplasm whereas the supranuclear 
cytoplasm was negative. Some cells did not stain at all or stained very weakly (Figure 
4). 
 
There were several reasons behind the recurrence of hyperoxaluria and oxalate 
nephropathy post-CIKTx. (i) Although we found the weak expression of oxalate 
transporter (SLC26A6) both in native intestine and intestinal allograft after the 
recurrence, we believe that this phenomenon could be the strongest reason for poor 
oxalate elimination (9-10). Moreover, other contributing reasons would be (ii) the kidney 
allograft with early dysfunction which was not able to excrete high levels of oxalate and 
(iii) the prolonged (>2 months) consumption of antibiotics post-transplantation interfering 
with the intestinal flora and leading to enteric hyperoxaluria, as shown by Lefaucheur et 
al (17) in native kidneys following nonrenal solid organ transplantation, such as heart, 
lung, and liver transplantation. We believe that mycophenolate mofetil-induced enteric 
hyperoxaluria, as shown by Jahromi et al (18) is not the case in our patient since 
mycophenolate mofetil was discontinued at 2 months post-transplantation due to its 
presumed side effects, such as diarrhea and bone marrow suppression.  
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The genetic defect in oxalate transporter (SLC26A6) in native duodenum and rectum 
cannot be corrected. However, if it was known before CIKTx, the strategy of performing 
a full multivisceral transplant (with the liver and duodenum) could have been 
considered. There is also an unknown question; whether the defect in oxalate 
transporter in the remaining portion of native duodenum (15-20cm) and rectum (15-
20cm) would suffice to induce oxalosis over full length working transplanted intestine. 
Moreover, in our case, the expression of SLC26A6 was significantly less intense in the 
transplanted small intestine as well, which adds another unknown in the field whether 
this was isolated to our case or all small intestinal transplants would have diminished 
SLC26A6 expression.   
 
The early dysfunction of the renal allograft due to the use of high pressors and blood 
transfusion could be avoided by the delayed implantation of the kidney allograft in 
CIKTx, as shown in combined liver-kidney transplantation by our group (19).  We 
usually delay the implantation of the kidney allograft up to 3 days in combined liver-
kidney transplantation, supporting the kidney allograft by continuous hypothermic 
machine perfusion (19). The delayed implantation of kidney allograft in combined liver-
kidney transplantation enabled us to hemodynamically stabilize our recipients post-liver 
transplantation, which offers a less hostile environment for the kidney allograft. The 
delayed approach kidney implantation allowed us to overcome the burden of the 
delayed graft function (0% in combined liver and delayed kidney transplantation). 
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Alternative strategy to reduce the stress and oxalate burden could be performing 
bilateral allograft nephrectomies prior to CIKTx. However, in order to maintain minimal 
urine output and lack of experience with CIKTx in patients with CKD and enteric 
hyperoxaluria at our center as well as in the literature, we performed bilateral allograft 
nephrectomies at the time of CIKTx. 
 
In conclusion, we believe that kidney transplantation alone in patients with CKD 
secondary to enteric hyperoxaluria should not be recommended due to high risk of 
recurrence. Although other centers showed good long-term outcomes in CIKTx, our 
patient experienced the recurrence of hyperoxaluria and chronic kidney disease due to 
the combination of the genetic defect in oxalate transporter, early kidney allograft 
dysfunction, and the prolonged consumption of antibiotics post-transplantation. 
Although the defect in the expression of oxalate transporter would be quite difficult to 
exclude in intestinal or kidney allografts before transplantation, the consideration should 
be given to avoid early kidney allograft dysfunction and the preservation of the intestinal 
flora.  
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Figure Legends: 
 
Figure 1: Time-line of surgeries and major events. 
(#) native kidney biopsy = severe oxalate nephropathy 
(*) biopsy of the 1st kidney transplant = severe oxalate nephropathy 
(**) biopsy of the 2nd kidney transplant = severe oxalate nephropathy 
(***) biopsy of the 3rd kidney transplant = severe oxalate nephropathy 
(∞) 02/2014= work-up for possible multivisceral / isolated intestinal + kidney 
transplantation. Liver biopsy showed normal liver architecture, and no fibrosis. Blood 
liver function tests were normal. Genetic testing for primary hyperoxaluria (AGXT / 
GRHPR / DHDSPL mutations) was negative. Therefore, combined isolated intestinal + 
kidney transplantation was decided to perform. 
CKD = chronic kidney disease, eGFR= estimated glomerular filtration rate, HD = 
hemodialysis, IF = intestinal failure, TPN = total parenteral nutrition 
 
Figure 2: Biopsy of kidney allografts 
(A) Biopsy of the second kidney allograft: H&E (x40) of the second kidney allograft 
showing oxalate crystal.  
 
(B) Biopsy of the third kidney allograft: H&E (x40) of the third kidney allograft showing 
oxalate crystals in non-polarized and polarized light microscopy.  
 
Figure 3: Serum creatinine (S-Cre) levels over the years. 
Serum creatinine levels from July 2009 to December 2015. 
 
Figure 4: Oxalate transporter (SLC26A6) staining. 
(A) Control normal small intestinal mucosa: Intense staining of the subnuclear as well as 
supranuclear cytoplasm of the epithelial cells. 
 
(B) Native duodenum: Less intensity of staining only in the subnuclear cytoplasm. 
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(C) Native rectum: almost no staining. 
 
(D) Small intestine allograft (4 months after the transplant): less intensity staining 
compared to control only in the subnuclear cytoplasm of the epithelial cells. 
 
(E) Small intestine allograft (10 months after the transplant): less intensity staining 
compared to control only in the subnuclear cytoplasm of the epithelial cells but better 
than 4 months after the transplant. 
 
 
Three micron thick sections were stained immunohistochemically with an antibody 
against SLC26A6 (Novus Biologicals, Littleton, CO). Briefly, sections from formalin fixed 
paraffin embedded tissues were deparaffinized and cleared in xylene. Antigen retrieval 
was carried out with EDTA at pH8. After blocking endogenous peroxidase, the sections 
were incubated with the primary antibody at a dilution of 1:1000 for 20 minutes at room 
temperature. The reaction was visualized using the Dako Flex Plus kit (Dako, 
Carpinteria, CA) using 3-3’-diaminobenizidine tetra hydrochloride as the chromogen. All 
images have x1000 magnification. 
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Figure 2A: 
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